Document Detail

Office management of peripheral arterial disease.
MedLine Citation:
PMID:  20800143     Owner:  NLM     Status:  MEDLINE    
Patients with peripheral arterial disease are at increased risk for all-cause mortality, cardiovascular mortality, and mortality from coronary artery disease. Smoking should be stopped, and hypertension, diabetes mellitus, and dyslipidemia should be treated. Statins reduce the incidence of intermittent claudication and increase exercise duration until the onset of intermittent claudication in patients with peripheral arterial disease and hypercholesterolemia. Antiplatelet drugs, such as aspirin or clopidogrel, angiotensin-converting enzyme inhibitors, and statins, should be given to all patients with peripheral arterial disease. Beta-blockers should be given if coronary artery disease is present. Exercise rehabilitation programs and cilostazol improve exercise time until the onset of intermittent claudication. Indications for lower-extremity angioplasty, preferably with stenting, or bypass surgery are incapacitating claudication interfering with work or lifestyle in patients; limb salvage in patients with limb-threatening ischemia as manifested by rest pain, nonhealing ulcers, infection, or gangrene; and vasculogenic impotence.
Wilbert S Aronow
Related Documents :
7795313 - Activation of the intracellular glutathione system by oxydative stress during cardiopul...
18073463 - Can a peripheral artery be used to detect venous to arterial circulation shunts?
17047893 - Pulmonary aneurysms and intracardiac thrombi due to behçet's disease in an african-ame...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of medicine     Volume:  123     ISSN:  1555-7162     ISO Abbreviation:  Am. J. Med.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-08-30     Completed Date:  2010-09-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0267200     Medline TA:  Am J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  790-2     Citation Subset:  AIM; IM    
Department of Medicine, New York Medical College, Valhalla, NY, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / therapeutic use
Ambulatory Care* / methods
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Coronary Artery Disease / complications,  drug therapy
Diabetes Complications / drug therapy
Dyslipidemias / complications,  drug therapy
Exercise Tolerance
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Hypertension / complications,  drug therapy
Intermittent Claudication / etiology,  therapy
Ischemia / therapy
Lower Extremity / blood supply*
Office Visits
Peripheral Vascular Diseases / diagnosis*,  drug therapy*,  etiology
Platelet Aggregation Inhibitors / therapeutic use
Risk Factors
Risk Reduction Behavior
Smoking / adverse effects
Smoking Cessation
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The reply.
Next Document:  Higher cardiovascular disease prevalence and mortality among younger blacks compared to whites.